GSK plc
GLAXF
$26.08
-$0.80-2.98%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.52% | 5.90% | 3.42% | 4.13% | 6.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.52% | 5.90% | 3.42% | 4.13% | 6.26% |
| Cost of Revenue | 4.47% | 5.66% | 7.61% | 7.14% | 8.45% |
| Gross Profit | 8.72% | 6.00% | 1.86% | 2.99% | 5.42% |
| SG&A Expenses | -14.41% | -14.96% | 17.40% | 20.79% | 22.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -173.97% | 17.69% | 62.91% | 74.58% | 62.66% |
| Total Operating Expenses | -5.03% | -1.81% | 15.43% | 17.73% | 18.54% |
| Operating Income | 59.64% | 33.63% | -26.75% | -29.77% | -25.70% |
| Income Before Tax | 121.19% | 121.45% | -5.72% | -23.02% | -41.54% |
| Income Tax Expenses | 119.42% | 120.98% | -7.52% | -22.05% | -29.09% |
| Earnings from Continuing Operations | 121.50% | 121.52% | -5.42% | -23.18% | -43.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -56.98% | -73.68% | -103.71% | -81.09% | -2.16% |
| Net Income | 131.02% | 128.01% | -13.09% | -29.53% | -46.81% |
| EBIT | 59.64% | 33.63% | -26.75% | -29.77% | -25.70% |
| EBITDA | 50.02% | 38.95% | -4.57% | -10.58% | -9.59% |
| EPS Basic | 132.20% | 128.62% | -13.33% | -29.99% | -47.12% |
| Normalized Basic EPS | 67.53% | 34.97% | -35.16% | -37.45% | -29.28% |
| EPS Diluted | 131.46% | 128.01% | -13.29% | -29.89% | -47.11% |
| Normalized Diluted EPS | 67.11% | 34.70% | -35.16% | -37.43% | -29.23% |
| Average Basic Shares Outstanding | -0.64% | -0.11% | 0.33% | 0.59% | 0.62% |
| Average Diluted Shares Outstanding | -0.52% | 0.01% | 0.43% | 0.68% | 0.70% |
| Dividend Per Share | 11.65% | 8.08% | 7.93% | 6.66% | 8.08% |
| Payout Ratio | -0.53% | -0.52% | 0.25% | 0.59% | 1.10% |